Masashi Miyauchi 宮内将

Researcher Number	40772801
Affiliation (based on the past Project Information) *help	2016 – 2019: 東京大学, 医学部附属病院, 特任助教
Review Section/Research Field	Principal Investigator Basic Section 54010:Hematology and medical oncology-related / Hematology
Keywords	Principal Investigator 治療抵抗性 / 造血器腫瘍 / 腫瘍幹細胞 / バイオマーカー / 薬剤耐性 / がん幹細胞 / 慢性骨髄性白血病 / 疾患由来iPS細胞

The significance of ADAM8 on chemoresistance of hematopoietic malignanciesPrincipal Investigator
- Principal Investigator
  
  Miyauchi Masashi
- Project Period (FY)
  2018 – 2019
- Research Category
  
  Grant-in-Aid for Early-Career Scientists
- Review Section
  
  Basic Section 54010:Hematology and medical oncology-related
- Research Institution
  The University of Tokyo
The elucidation of the mechanism of imatinib-resistance in CML stem cells using disease specific iPSCsPrincipal Investigator
- Principal Investigator
  
  Masashi Miyauchi
- Project Period (FY)
  2016 – 2017
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Hematology
- Research Institution
  The University of Tokyo

All 2020 2018 2017 2016

All Journal Article Presentation Book Patent

[Book] 日本臨床2020
- Author(s)
  宮内　将、黒川　峰夫
- Total Pages
  5
- Publisher
  日本臨床社
- Data Source
  KAKENHI-PROJECT-18K16111
[Journal Article] Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate.2018
- Author(s)
  1.Taoka K, Arai S, Kataoka K, Hosoi M, Miyauchi M, Yamazaki S, Honda A, Aixinjueluo W, Kobayashi T, Kumano K, Yoshimi A, Otsu M, Niwa A, Nakahata T, Nakauchi H, Kurokawa M.
- Journal Title
  
  Scientific Reports
  
  Volume: 8 Issue: 1 Pages: 15855-15867
- DOI
  10.1038/s41598-018-34193-1
- NAID
  120006534582
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09631, KAKENHI-PROJECT-18K16111, KAKENHI-PROJECT-16H02661, KAKENHI-PROJECT-18H04052
[Journal Article] ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells2018
- Author(s)
  Miyauchi Masashi、Koya Junji、Arai Shunya、Yamazaki Sho、Honda Akira、Kataoka Keisuke、Yoshimi Akihide、Taoka Kazuki、Kumano Keiki、Kurokawa Mineo
- Journal Title
  
  Stem Cell Reports
  
  Volume: 10 Issue: 3 Pages: 1115-1130
- DOI
  10.1016/j.stemcr.2018.01.015
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PUBLICLY-16H01196, KAKENHI-PROJECT-16K19568, KAKENHI-PROJECT-17K09631
[Journal Article] 骨髄増殖性腫瘍由来iPS細胞の樹立と病態解析2016
- Author(s)
  宮内　将
- Journal Title
  
  血液内科
  
  Volume: 73 Pages: 355-359
- Data Source
  KAKENHI-PROJECT-16K19568
[Patent] 慢性骨髄性白血病の検査方法及び検査用キット、並びにチロシンキナーゼ阻害剤に対して耐性を有する慢性骨髄性白血病細胞の単離方法2017
- Inventor(s)
  宮内将、黒川峰夫
- Industrial Property Rights Holder
  東京大学TLO
- Industrial Property Rights Type
  特許
- Industrial Property Number
  2017-026287
- Filing Date
  2017-02-15
- Data Source
  KAKENHI-PROJECT-16K19568
[Presentation] ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells.2018
- Author(s)
  宮内　将
- Organizer
  第１４回血液学若手研究者勉強会
- Data Source
  KAKENHI-PROJECT-18K16111
[Presentation] ADAM8 (CD156) is identified as a Novel Antigen of TKI-resistant Chronic Myeloid Leukemia Cells, Using Patient-Derived Induced Pluripotent Stem Cells2017
- Author(s)
  Masashi Miyauchi and Mineo Kurokawa
- Organizer
  日本がん分子標的治療学会
- Data Source
  KAKENHI-PROJECT-16K19568
[Presentation] Patient-Derived Induced Pluripotent Stem Cells Identify ADAM8 as an Antigen of TKI-resistant Chronic Myeloid Leukemia Cells.2017
- Author(s)
  Masashi Miyauchi, Junji Koya, Shunya Arai, Sho Yamazaki, Akira Honda, Keisuke Kataoka, Akihide Yoshimi, Kazuki Taoka, Keiki Kumano, and Mineo Kurokawa
- Organizer
  keystone symposium
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K19568
[Presentation] Patient-Derived Induced Pluripotent Stem Cells Revealed ADAM8/CD156 as a Novel Marker of TKI-Resistant Chronic Myeloid Leukemia Cells.2016
- Author(s)
  Miyauchi M, Arai S, Honda A, Yamazaki S, Kataoka K, Yoshimi A, Taoka K, Kumano K, Kurokawa M.
- Organizer
  American society of hematology annual meeting
- Place of Presentation
  San Diego, CA, USA.
- Year and Date
  2016-12-03
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K19568
[Presentation] Pre-HPCs derived from CML-iPSCs, as a platform of CML stem cells, reveal a novel marker of TKI-resistant CML cells.2016
- Author(s)
  Miyauchi M, Arai S, Honda A, Yamazaki S, Kataoka K, Yoshimi A, Taoka K, Kumano K, Kurokawa M.
- Organizer
  日本癌学会
- Place of Presentation
  横浜
- Year and Date
  2016-10-06
- Data Source
  KAKENHI-PROJECT-16K19568
[Presentation] Pre-HPCs derived from CML-iPSCs represent a platform for analysis of TKI-resistant CML stem cells.2016
- Author(s)
  Miyauchi M, Arai S, Honda A, Yamazaki S, Kataoka K, Yoshimi A, Taoka K, Kumano K, Kurokawa M.
- Organizer
  日本血液学会
- Place of Presentation
  横浜
- Year and Date
  2016-10-13
- Data Source
  KAKENHI-PROJECT-16K19568
[Presentation] Pre-hematopoietic progenitor cells (CD34+ CD43+ CD45-) derived from CML-iPSCs as powerful platform for analysis of TKI-resistant CML stem cells.2016
- Author(s)
  Miyauchi M, Arai S, Honda A, Yamazaki S, Kataoka K, Yoshimi A, Taoka K, Kumano K, Kurokawa M.
- Organizer
  International Society of Stem Cell Research
- Place of Presentation
  San Francisco, CA, USA.
- Year and Date
  2016-06-22
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K19568
[Presentation] Modeling Tyrosine Kinase Inhibitor-resistant Chronic Myelogenous Leukemia by Patient-derived Induced Pluripotent Stem Cells2016
- Author(s)
  Miyauchi M, Arai S, Honda A, Yamazaki S, Kataoka K, Yoshimi A, Taoka K, Kumano K, Kurokawa M.
- Organizer
  5th JAC-AACR Special Joint Conference (Japanese Cancer Association, American Association of Cancer Research)
- Place of Presentation
  舞浜
- Year and Date
  2016-07-13
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K19568

1. 熊野恵城

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
2. 黒川峰夫

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

Masashi Miyauchi 宮内 将

Research Projects

Research Products

Co-Researchers

The significance of ADAM8 on chemoresistance of hematopoietic malignanciesPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

The elucidation of the mechanism of imatinib-resistance in CML stem cells using disease specific iPSCsPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Book] 日本臨床2020

Author(s)

Total Pages

Publisher

Data Source

[Journal Article] Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate.2018

Author(s)

Journal Title

DOI

NAID

Data Source

[Journal Article] ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells2018

Author(s)

Journal Title

DOI

Data Source

[Journal Article] 骨髄増殖性腫瘍由来iPS細胞の樹立と病態解析2016

Author(s)

Journal Title

Data Source

[Patent] 慢性骨髄性白血病の検査方法及び検査用キット、並びにチロシンキナーゼ阻害剤に対して耐性を有する慢性骨髄性白血病細胞の単離方法2017

Inventor(s)

Industrial Property Rights Holder

Industrial Property Rights Type

Industrial Property Number

Filing Date

Data Source

[Presentation] ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells.2018

Author(s)

Organizer

Data Source

[Presentation] ADAM8 (CD156) is identified as a Novel Antigen of TKI-resistant Chronic Myeloid Leukemia Cells, Using Patient-Derived Induced Pluripotent Stem Cells2017

Author(s)

Organizer

Data Source

[Presentation] Patient-Derived Induced Pluripotent Stem Cells Identify ADAM8 as an Antigen of TKI-resistant Chronic Myeloid Leukemia Cells.2017

Author(s)

Organizer

Data Source

[Presentation] Patient-Derived Induced Pluripotent Stem Cells Revealed ADAM8/CD156 as a Novel Marker of TKI-Resistant Chronic Myeloid Leukemia Cells.2016

Author(s)

Organizer

Place of Presentation

Year and Date

Data Source

[Presentation] Pre-HPCs derived from CML-iPSCs, as a platform of CML stem cells, reveal a novel marker of TKI-resistant CML cells.2016

Author(s)

Organizer

Place of Presentation

Year and Date

Data Source

[Presentation] Pre-HPCs derived from CML-iPSCs represent a platform for analysis of TKI-resistant CML stem cells.2016

Author(s)

Organizer

Place of Presentation

Year and Date

Data Source

[Presentation] Pre-hematopoietic progenitor cells (CD34+ CD43+ CD45-) derived from CML-iPSCs as powerful platform for analysis of TKI-resistant CML stem cells.2016

Author(s)

Organizer

Place of Presentation

Year and Date

Data Source

[Presentation] Modeling Tyrosine Kinase Inhibitor-resistant Chronic Myelogenous Leukemia by Patient-derived Induced Pluripotent Stem Cells2016

Masashi Miyauchi 宮内将